The third scenario, in which the booster dose was with the Pfizer vaccine, showed the highest percentages of effectiveness: 56.8% against symptomatic infections and 85.5% against severe cases.
The findings suggest implications for booster shots. While traditional boosters work well for childhood vaccines by increasing antibody levels, the approach becomes more complex with evolving viruses.